Effect of Exposure to Small Pharmaceutical Promotional Items on Treatment Preferences

Grande, David; Frosch, Dominick L.; Perkins, Andrew; Kahn, Barbara E.

doi:10.1001/archinternmed.2009.64

Cited by 93 publications

(96 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies had also shown that short seminars that focus on the subject of interactions with pharmaceutical companies have not resulted in Siddiqi et al 1631 lasting changes in behavior or attitudes (Randall and Rosenbaum, 2005;van et al, 2006). A study had also showed that small gifts to medical students increased positive attitudes regarding the advertised substances at a later stage (Grande et al, 2009). Another study showed that doctors whose prescription costs were high were more likely to receive visits from sales representatives and did so more often (Watkins et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

Relevant influence of promotional tools by pharmaceutical industry on prescribing behaviors of doctors: A cross-sectional survey in Pakistan

Siddiqi¹,

Hussain²,

Parveen³

et al. 2011

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

Worldwide drug expenditures have been one of the main concerns of health care managers, and its containment is one of the primary goals of health care authorities. The present study was conducted through a cross sectional survey in Pakistan during January to June, 2010 not only to find out the importance and influence of promotional tools used by pharmaceutical industry on prescribing behaviors of doctors/consultants, but to also establish comparison between doctors/consultants versus medical representatives and consultant versus doctors with an auxiliary of difference between local and multinational company's representative. The study revealed that promotional tools are considered vital from doctors and medical representatives' point of view. There exists significant difference in doctors and consultant's perception for sponsorships and low value gifts, but no difference in scientific promotional tools. No significant difference exits in perception of medical representatives of multinational and local company representatives. The companies tried to come up as per expectations of doctors to build its reputation and good image by employing different promotional tools. The study also revealed that marketing managers, product managers, chief executive officers or any decision makers involved in budget allocations and making promotional strategy should not rely heavily on medical representative's feedback as their perception is different from doctors/consultants about relevant importance of each promotional tool. The study will also help product managers and CEOs while allocating promotional budgets and developing promotional mix strategy, to gain maximum return out of investment. Detailed doctors' demographics can further be researched as predictor for preferring any promotional tools.

show abstract

Section: Discussionmentioning

confidence: 99%

Relevant influence of promotional tools by pharmaceutical industry on prescribing behaviors of doctors: A cross-sectional survey in Pakistan

Siddiqi¹,

Hussain²,

Parveen³

et al. 2011

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…When the effect of subtle exposures to branded pharmaceutical promotional items was tested experimentally in medical students, pharmaceutical marketing was found to influence implicit attitudes of brand preference. Of interest in this same study, the effect of drug marketing was reversed among fourth-year medical students whose institution had a restrictive policy to limit pharmaceutical marketing [21]. Thus, we may not know ourselves as well as we think we do.…”

mentioning

confidence: 94%

Opioid Prescribing: How Well Do We Know Ourselves?

Wightman

Nelson

2016

J. Med. Toxicol.

View full text Add to dashboard Cite

Get your facts first, then you can distort them as you please.-Mark Twain BI would rather over-prescribe and risk some medication diversion or non-medical use, than under-prescribe and not treat a patient's pain.^This statement, taken from a survey published in the current issue of JMT by Pomerleau et al. 2016 [1], was used to assess clinicians' self-reported attitude about the challenge in meeting individual patient needs while balancing public health risk. The statement essentially pinpoints the current dilemma in the ED: alleviation of suffering in an individual may expose that patient or others (through misuse or diversion) to the risk of opioid analgesic (OA) abuse, addiction, overdose, and death. Pain-related complaints are the most common reason for Emergency Department (ED) visits [2,3], and ED providers are among the top five medical specialist groups writing prescriptions for OAs in patients under 40 years of age [4]. However, only 17 % of ED patients are given a prescription for an OA on discharge and the majority of prescriptions dispensed are for a small number of immediate release pills [5,6]. Still, iatrogenic opioid abuse and addiction remain a concern, because half of ED patients with opioid-use disorders were first exposed to an opioid by a prescription from a medical provider [7].Responsible opioid analgesic prescribing is paramount in our efforts to combat the epidemic of opioid abuse and promote safe opioid use, but little is currently known about which factors drive decision-making among emergency department (ED) prescribers of OAs. Pomerleau et al. highlights the complexity of the decision-making process and brings forth a number of interesting issues. Through a series of queries, the study explores the factors providers believe affect their OA prescribing practices, as well as their attitudes toward OA prescribing. Of course, individual provider opinions and attitudes cannot provide the complete picture. Patient age, race, type of insurance, provider training and experience, functionality of PDMPs, and geographic location are a few of the many factors highlighted in the literature to affect OA prescribing decisions.Whether to prescribe an OA for any given patient not only depends on the aforementioned patient and provider factors and the culture of the work environment, but also on the quality and type of patient doctor communication. One study showed that when faced with identical hypothetical case scenarios, ED physicians' decisions whether to prescribe an OA varied greatly [14]. For the same clinical scenario, subtle differences in the patient-doctor interaction (for example, a patient requesting a specific drug or an additional dose of pain medication) could change the likelihood of prescribing substantially [18]. To support this unconscious bias, Pomerleau, et al. uncovered some interesting paradoxes. For example, survey respondents report that they would be less likely to write a prescription for a patient with an opioid use disorder, but they also state their skills to identify pat...

show abstract

“…However, physician attitudes are also influenced by other factors, such as institutional prescribing guidelines and the effect of pharmaceutical company promotional campaigns [23,24,25]. For instance, promotional campaigns may have highlighted specific therapeutic attributes as important for the management of asthma, and these may be reflected in the results of a study such as this.…”

Section: Discussionmentioning

confidence: 99%

Inhaled Corticosteroid/Long-Acting β<sub>2</sub>-Agonist Combination Therapy for Asthma: Attitudes of Specialists in Europe

Bousquet

Winchester²,

Papi³

et al. 2011

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: As new combinations of inhaled corticosteroids (ICSs) and long-acting β₂-agonists (LABAs) become available for the treatment of asthma, it will be important to determine criteria against which they can be evaluated. The aim of this study was to assess which attributes of combination therapy physicians consider most important. Methods: Primary and secondary care asthma specialists (n = 32) were recruited for an expert Delphi process that was performed over three rounds to determine attributes perceived to be important in the selection of combination therapy. A pan-European survey was carried out to assess the attitudes, perceptions and prescribing behaviour of a larger population (n = 1,861) of physicians with a specialist interest in asthma treatment. Results: The expert Delphi panel (response rate 59.4%) agreed that the availability of a range of doses (88% agreement in the final round), the efficacy of the combination (81%) and the safety and tolerability of the therapy (81%) were important attributes of ICS/LABA combination treatment. The potency of the ICS (69%) and the speed of onset of the LABA (69%) were also prioritized. The results of the attitudinal survey (eligibility rate 54.1%) showed that the same factors were considered important in everyday clinical practice. Conclusions: These studies identified which attributes of an ICS/LABA treatment are considered most important by an expert panel and a broader group of physicians; further research is warranted to better understand the influences that drive physician opinions.

show abstract

Effect of Exposure to Small Pharmaceutical Promotional Items on Treatment Preferences

Abstract: Subtle exposure to small pharmaceutical promotional items influences implicit attitudes toward marketed products among medical students. We observed a reversal of this effect in the setting of restrictive policies and more negative school-level attitudes toward marketing.

Cited by 93 publications

References 23 publications

Relevant influence of promotional tools by pharmaceutical industry on prescribing behaviors of doctors: A cross-sectional survey in Pakistan

Relevant influence of promotional tools by pharmaceutical industry on prescribing behaviors of doctors: A cross-sectional survey in Pakistan

Opioid Prescribing: How Well Do We Know Ourselves?

Inhaled Corticosteroid/Long-Acting β<sub>2</sub>-Agonist Combination Therapy for Asthma: Attitudes of Specialists in Europe

Contact Info

Product

Resources

About